domingo, 8 de marzo de 2015

No association between CYP3A4*22 and statin effectiveness in reduci... - PubMed - NCBI

No association between CYP3A4*22 and statin effectiveness in reduci... - PubMed - NCBI



 2014 Aug;15(11):1471-7. doi: 10.2217/pgs.14.90.

No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.

Abstract

AIM:

Genetic variation has been shown to influence statin response in terms of lowering LDL cholesterol. The recently discovered CYP3A4*22 allele (defined as rs35599367) has been shown to affect statin-induced LDL cholesterol lowering. Our objective was to investigate whether this polymorphism modifies the risk reduction for myocardial infarction (MI) by statins.

PATIENTS & METHODS:

We analyzed the interaction between the *22 minor allele and statin use in the independent Utrecht Cardiovascular Pharmacogenetics study and Rotterdam Study, using logistic and Cox regression models.

RESULTS:

In total, 771 MI cases and 6131 controls were included in the analyses. There was no effect of the CYP3A4*22 allelic status in the studies separately, nor when the estimates from both studies were combined (interaction odds ratio: 1.27; 95% CI: 0.73-2.21; p = 0.40 for carriers of the minor T-allele).

CONCLUSION:

We found no association of the CYP3A4*22 minor allele (rs35599367) with the effectiveness of statins in reducing MI risk.

KEYWORDS:

CYP3A4; CYP3A4*22; myocardial infarction; pharmacogenetics; rs35599367; statins

PMID:
 
25303298
 
[PubMed - in process]

No hay comentarios:

Publicar un comentario